---
title: "TJPC: Received the approval notice for the listing application of chemical raw materials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255158286.md"
description: "TJPC announced that it recently received the \"Approval Notice for the Market Application of Chemical Raw Materials\" for Difluprednate issued by the National Medical Products Administration. Difluprednate is a topical corticosteroid that can inhibit inflammatory responses caused by various irritants. The main dosage form currently available on the market is eye drops, primarily used to treat inflammation and pain related to eye surgery. According to the IQVIA database, the global sales of Difluprednate formulations are projected to be USD 49 million and USD 41 million in 2023 and 2024, respectively"
datetime: "2025-08-29T09:01:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255158286.md)
  - [en](https://longbridge.com/en/news/255158286.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255158286.md)
generator: "portal-rs"
---

# TJPC: Received the approval notice for the listing application of chemical raw materials

TJPC announced that it recently received the "Approval Notice for the Market Application of Chemical Raw Materials" for difluprednate issued by the National Medical Products Administration. Difluprednate is a topical corticosteroid that can inhibit inflammatory responses caused by various irritants. The main formulation available in the market is eye drops, primarily used for treating inflammation and pain related to eye surgeries. According to the IQVIA database, the global sales of difluprednate formulations are projected to be USD 49 million and USD 41 million in 2023 and 2024, respectively

### Related Stocks

- [600488.CN](https://longbridge.com/en/quote/600488.CN.md)

## Related News & Research

- [Trump Signs Order to Create US Space Academy, Eyes Moon Landing Before End of Presidency](https://longbridge.com/en/news/297402922.md)
- [Biocytogen Pharmaceuticals announces extraordinary general meeting](https://longbridge.com/en/news/297148979.md)
- [This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday](https://longbridge.com/en/news/297053341.md)
- [ByHeart Says FDA Confirms Review Of ByHeart's Root Cause Investigation And Action Plan](https://longbridge.com/en/news/297358769.md)
- [08:39 ETPredoc Launches Curated Data Layer to Make Fragmented Medical Records Usable](https://longbridge.com/en/news/297187951.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**